Exploratory Asset

About Veradermics

Veradermics is a late-stage biopharma company founded by practicing dermatologists to develop novel therapeutics for high-prevalence, under-innovated dermatologic conditions. Its core strategy leverages deep clinical expertise to reformulate proven compounds, de-risking development and focusing on real-world patient needs. The company's lead asset, VDPHL01 for pattern hair loss, is in Phase 3 trials, positioning it to potentially capture a multi-billion dollar market with a first-in-class oral therapy.

About Veradermics

Veradermics is a late-stage biopharma company founded by practicing dermatologists to develop novel therapeutics for high-prevalence, under-innovated dermatologic conditions. Its core strategy leverages deep clinical expertise to reformulate proven compounds, de-risking development and focusing on real-world patient needs. The company's lead asset, VDPHL01 for pattern hair loss, is in Phase 3 trials, positioning it to potentially capture a multi-billion dollar market with a first-in-class oral therapy.

About Veradermics

Veradermics is a late-stage biopharma company founded by practicing dermatologists to develop novel therapeutics for high-prevalence, under-innovated dermatologic conditions. Its core strategy leverages deep clinical expertise to reformulate proven compounds, de-risking development and focusing on real-world patient needs. The company's lead asset, VDPHL01 for pattern hair loss, is in Phase 3 trials, positioning it to potentially capture a multi-billion dollar market with a first-in-class oral therapy.

Therapeutic Areas

Other Alopecia Areata Drugs